A poorly characterized protein, historically thought to be a chaperon or enzyme, may actually be a key player in prostate ...

The influenza A virus (IAV) has been the cause of six major flu pandemics, responsible for 50 to 100 million deaths globally. In the U.S. alone, it is estimated that despite seasonally updated ...

A lthough still in its early days, CRISPR has already been called the most powerful scientific tool of the century. Using ...

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

Lozano is a rare disease mom, neuroscience Ph.D. candidate at UC Davis, and board member for the PURA Syndrome Foundation. In May, a historic moment in science and medicine was captured in a single ...

In the latest close session, CRISPR Therapeutics AG (CRSP) was down 6.54% at $68.29. The stock trailed the S&P 500, which registered a daily gain of 1.56%. On the other hand, the Dow registered a gain ...

If you have been staring at CRISPR Therapeutics stock lately, wondering whether it is time to buy, hold, or rethink your position, you are far from alone. Over the past week, the stock has surged 16.1 ...

Labroots invites you to the 8th Annual CRISPR Virtual Event Series 2025, taking place on October 22nd, 2025! This event will explore the expanding frontier of CRISPR technology, with sessions covering ...

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...